The Arg972 insulin receptor substrate-1 (IRS-1) variant has been hypothesized to play a role in pancreatic β-cell stimulus-coupled insulin secretion and survival. We analyzed the relations between type 1 diabetes and the Arg972 IRS-1 variant. The frequency of the IRS-1 Arg972 variant was investigated in two independent sets of unrelated patients: a case-control study and a collection of type 1 diabetes simplex families. In the former group, frequency of the IRS-1 Arg972 variant was significantly increased in the patients (P = 0.0008), conferring an OR of 2.5. Transmission disequilibrium analysis of data obtained from the family set revealed that the Arg972 IRS-1 variant was transmitted from heterozygous parents to affected probands at a frequency of 70.2% (P <0.02). Arg972 IRS-1 frequency showed no significant correlation with HLA genotypic risk for type 1 diabetes. Arg972 IRS-1 type 1 diabetic patients also had lower fasting plasma concentrations of C-peptide at the time of diagnosis with respect to patients carrying the wild-type IRS-1 (0.49 ± 0.058, n = 34, and 0.76 ± 0.066, n = 134, respectively [means ± SE]; P = 0.051). Our findings suggest a role for Arg972 IRS-1 in conferring risk for the development of type 1 diabetes.
- IRS-I, insulin receptor substrate-1
- P13, phosphatidylinositol-3
- PPV, positive predictive value
- TDT, transmission disequilibrium test
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism